. 2014 May 23;16(3):R50. doi: 10.1186/bcr3661

Table 3.

Efficacy outcomes by tumor HER2 expression below the median and equal to or greater than the median

	Median PFS, months
HER2 expression^a	HT	T-DM1	HR relative to HT (95% CI)
All patients	(n = 70)	(n = 67)	0.59 (0.36, 0.97)
All patients	9.2	14.2	0.59 (0.36, 0.97)
< Median	(n = 32)	(n = 26)	0.85 (0.44, 1.67)
< Median	9.8	10.6	0.85 (0.44, 1.67)
≥ Median	(n = 29)	(n = 29)	0.39 (0.18, 0.85)
≥ Median	8.8	Not reached	0.39 (0.18, 0.85)
	ORR,%
HER2 expression^a	HT	T-DM1	Odds ratio relative to HT (95% CI)
All patients	(n = 69)	(n = 67)	1.26 (0.63, 2.55)
All patients	58.0	64.2	1.26 (0.63, 2.55)
< Median	(n = 31)	(n = 26)	0.84 (0.30, 2.41)
< Median	58.1	53.8	0.84 (0.30, 2.41)
≥ Median	(n = 29)	(n = 29)	1.58 (0.50, 4.98)
≥ Median	65.5	72.4	1.58 (0.50, 4.98)

^aHER2 mRNA data were available for 61 of 70 patients in the HT arm and for 55 of 67 patients in the T-DM1 arm. HER2, human epidermal growth factor receptor 2; HT, trastuzumab plus docetaxel; ORR, objective response rate; PFS, progression-free survival; T-DM1, trastuzumab emtansine.